Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 1INTERVENTIONAL

Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of Pulmonary fibrosis than 18F-FDG PET/CT.

Who May Be Eligible (Plain English)

Who May Qualify: - suspected or confirmed pulmonary fibrosis patients; - signed written consent. Who Should NOT Join This Trial: - pregnancy; - breastfeeding; - known allergy against FAPI - any medical condition that in the opinion of the investigator may significantly interfere with study compliance Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * suspected or confirmed pulmonary fibrosis patients; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * known allergy against FAPI * any medical condition that in the opinion of the investigator may significantly interfere with study compliance

Treatments Being Tested

DRUG

68Ga-FAPI

Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.

DRUG

18F-FDG

Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.

Locations (1)

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China